• ADVANCE-ON demonstrates that lowering blood pressure below 140/80 mmHg with perindopril-indapamide (Preterax) in patients with type 2 diabetes during 4.3 years, leads to significant but attenuated mortality reduction after 6 years of post trial follow-up, with reductions in total and cardiovascular mortality of 9% and 12% respectively.
• This is the first study ever to demonstrate sustained post-trial benefits of blood pressure lowering therapy on cardiovascular and total mortality in patients with type 2 diabetes.
• ADVANCE-ON highlights the benefits of an early initiation and maintenance of a perindopril-indapamide (Preterax) strategy for optimal and continuous live saving benefits for patients with type 2 diabetes.